Zhongchao Inc. — 2020 Annual Report Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual Form 20-F, not a standalone fourth-quarter filing; quarterly results are not clearly provided in the filing text. Financial statements are audited and prepared under U.S. GAAP. Unless noted, amounts are U.S. dollars.
Business context
Zhongchao provides online and onsite healthcare information, education, and training in China through MDMOOC and Sunshine Health Forums, and launched patient-management services under Zhongxun in 2020. Most revenue comes from MDMOOC-related customer projects, including medical courses and patient-aid program services. The Cayman Islands parent conducts its China business primarily through a variable interest entity (VIE) structure.
Financial performance and position
| Metric | 2020 | 2019 | Change or context |
|---|---|---|---|
| Revenue | $17.99 million | $14.88 million | Up 20.9% |
| Gross profit / margin | $11.87 million / 66.0% | $10.23 million / 68.7% | Margin down 2.7 percentage points |
| Operating income | $4.49 million | $3.64 million | Up 23.3% |
| Net income | $4.46 million | $4.00 million | Up 11.4% |
| Net income attributable to Zhongchao shareholders | $4.46 million | $4.05 million | Basic and diluted EPS: $0.183 vs. $0.187 |
| Operating cash flow | $(1.04) million | $1.41 million | Turned negative despite higher net income |
| Cash and cash equivalents | $15.07 million | $7.83 million | More than doubled |
| Working capital | $26.61 million | $12.15 million | Current assets of $29.60 million; current liabilities of $2.98 million |
| Total assets / liabilities | $34.82 million / $2.98 million | $17.74 million / $2.40 million | No bank borrowings reported at year-end |
Operating cash flow was pressured chiefly by a $5.49 million increase in accounts receivable and a $1.14 million increase in other current assets. Receivables were $10.32 million at year-end, up from $5.08 million; the company reported a $336,367 write-off during 2020, while year-end doubtful-account allowances were reported as zero. The filing attributes the cash-flow strain partly to longer payment periods from NFP customers.
Investing cash outflow was $4.09 million, including purchases of listed securities and a limited partnership investment, plus property deposits. Financing cash inflow was $11.50 million, primarily from the February 2020 IPO and over-allotment. The company reported no material off-balance-sheet arrangements and $62,801 of remaining lease payments due within one year.
Material changes and operating developments
- Patient-aid project orders drove the revenue increase. Patient-aid projects covered nearly 45,000 patients by year-end; management expected the programs to reach approximately 65,000 patients by the end of 2021.
- Revenue mix shifted: NFP customers represented 87.2% of 2020 revenue, versus 72.4% in 2019; pharmaceutical enterprises represented 10.5%, versus 27.6%. The filing says pharmaceutical companies increasingly placed orders through NFPs.
- Two customers accounted for 26.9% and 19.7% of 2020 revenue. Two customers also represented 22.6% and 19.2% of year-end receivables.
- Cost of revenue rose 31.4%, faster than sales, reflecting higher expert fees and outsourced labor associated with patient-aid projects. Selling and marketing expense rose 7.7%; general and administrative expense rose 23.8%, including the receivables write-off and public-company costs. R&D expense declined to $816,553 from $864,320.
- The company raised approximately $13.26 million in gross IPO proceeds, before underwriting discounts, commissions, and expenses. It reported using IPO proceeds for course content, technology upgrades, and business expansion.
Outlook, risks, and unusual items
- Management outlook: The company said it expected long-term revenue growth as work resumed in China and expected to maintain high gross margins. These are forward-looking statements, not formal quantified guidance; the filing provides no specific 2021 revenue or earnings forecast.
- COVID-19: Employees worked remotely from mid-January to early April 2020. Some onsite courses were delayed, and about 10% were converted to online; online courses increased 15% year over year. The company generated more than $1.5 million from its COVID-19 curriculum in 2020. Management said the longer-term impact remained uncertain.
- Financial reporting controls: Management concluded disclosure controls were ineffective at December 31, 2020 and identified material weaknesses involving monitoring/review controls and U.S. GAAP and SEC-reporting expertise. Remediation efforts included outside consulting, staff training, and work to establish an internal audit function. No auditor attestation on internal controls was provided.
- VIE and China regulatory exposure: The company depends on contractual VIE arrangements to operate its China business. Their enforceability and treatment under evolving foreign-investment, online-content, education, privacy, and licensing rules remain uncertain. The filing identifies possible licensing requirements for audio-visual, online publishing, and internet culture activities that the company said it had not obtained, while stating it did not believe they were required.
- Governance and ownership: CEO Weiguang Yang’s Class B shares carry 15 votes each and represented approximately 80.9% of voting power. The company does not expect to pay dividends in the foreseeable future.
- Investment and other unusual items: The company invested in a limited partnership holding an interest in a private immunotherapy company; it recorded a $25,622 equity-method loss. Subsequent to year-end, it agreed to lend an unrelated party $900,000 for 12 months at 2% and completed payments for Japan office property and a China foreclosure property.
- Currency and collections: The business operates mainly in RMB, while reporting in U.S. dollars, and it does not hedge foreign-exchange exposure. Receivable concentration and collection timing are important risks.
Most important facts for investors to verify
- Whether the substantial receivables increase and negative operating cash flow translate into timely collections, and whether the zero year-end allowance remains appropriate after the 2020 write-off.
- Customer concentration, renewal/order visibility, and the economics of revenue routed through NFPs, including whether the 2020 revenue mix is sustainable.
- Progress and independently documented effectiveness of remediation for the disclosed material weaknesses and ineffective disclosure controls.
- Current legal, regulatory, and licensing status of the VIE structure and online services, and any material developments affecting the enforceability of the VIE arrangements.
- The status and terms of the HF warrant: the filing includes 1,350,068 warrant shares in reported outstanding-share figures although the shares were described as subject to regulatory and funding conditions; verify actual issuance, ODI approvals, and dilution.
- The limited partnership investment disclosures: verify the company’s actual commitment and funding, since the filing describes differing subscription amounts in different sections, and assess the investee’s performance and exit terms.
- Use and availability of cash, including restricted PRC net assets, property purchases, and the subsequent $900,000 loan; also verify the recoverability and terms of the loan.